Today: 22 March 2026
Subscribe
Browse Category

NYSE:LLY 6 January 2026 - 13 January 2026

Nvidia stock in premarket: H200 China payment clarification, Lilly AI lab and TSMC earnings in focus

Nvidia stock in premarket: H200 China payment clarification, Lilly AI lab and TSMC earnings in focus

Nvidia shares were flat in premarket trading after the company said customers in China won’t need to pay upfront for its H200 AI chips. Nvidia and Eli Lilly announced a $1 billion, five-year partnership to build an AI drug research lab in the Bay Area. Chip stocks rose, with Taiwan Semiconductor up nearly 2.5% ahead of its Jan. 15 earnings report.
13 January 2026
·····
Nvidia stock barely moves after hours as $1 billion Eli Lilly AI lab plan lands

Nvidia stock barely moves after hours as $1 billion Eli Lilly AI lab plan lands

Nvidia and Eli Lilly will invest up to $1 billion over five years in a joint AI drug discovery lab in the San Francisco Bay area, using Nvidia’s latest chips. Nvidia shares closed at $184.88, up 0.01%, and hovered near $184.94 after hours. The exact lab location will be announced in March. Investors are watching TSMC’s earnings report on January 15 and Nvidia’s on February 25.
12 January 2026
···
Nvidia stock gains on Eli Lilly $1 billion AI lab plan as traders eye TSMC, earnings

Nvidia stock gains on Eli Lilly $1 billion AI lab plan as traders eye TSMC, earnings

Nvidia and Eli Lilly will invest up to $1 billion in a Bay Area AI drug discovery lab over five years, sending Nvidia shares up 0.8% to $186.37 and Lilly up 0.2% to $1,066.14. AMD, Broadcom, and TSMC also rose as AI-focused stocks lifted the Nasdaq. TSMC reports earnings Jan. 15, with analysts expecting a 27% Q4 profit jump on AI chip demand. Nvidia’s next earnings are due Feb. 25.
12 January 2026
···
Nvidia stock wobbles after $1B Eli Lilly AI lab plan as CPI and TSMC loom

Nvidia stock wobbles after $1B Eli Lilly AI lab plan as CPI and TSMC loom

Nvidia and Eli Lilly will invest $1 billion over five years in a joint research lab in the San Francisco Bay Area, aiming to use Nvidia’s new AI chips to accelerate drug discovery. Nvidia shares slipped 0.2% to $184.42 by 10:30 a.m. ET. Thermo Fisher Scientific will also collaborate with Nvidia on lab automation. The new site is expected to open by the end of March.
12 January 2026
····
Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly shares rose about 0.7% Monday after announcing a $1 billion, five-year AI drug discovery lab partnership with Nvidia. The Bay Area facility, using Nvidia’s Vera Rubin chips, will open in March with teams from both firms. Investors are watching for updates from CEO David Ricks at the J.P. Morgan Healthcare Conference on Tuesday and Lilly’s earnings call on Feb. 4.
12 January 2026
······
Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Eli Lilly shares fell 1.99% to $1,063.56 Friday, trailing a record-setting S&P 500. Amazon Pharmacy began selling Novo Nordisk’s Wegovy pill for $149 a month, raising concerns about pricing pressure in obesity drugs. Lilly is set to address investors at the J.P. Morgan Healthcare Conference on Tuesday.
11 January 2026
······
Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

U.S. healthcare stocks fell this week, with the XLV ETF down 0.5% to $157.31, even as the S&P 500 hit a record high. Two biotech firms, Eikon Therapeutics and Veradermics, filed for IPOs. Healthcare M&A value rose 56% in 2025 to $403 billion, despite fewer deals. Insmed reported preliminary 2025 ARIKAYCE sales of $433.8 million and set a 2026 revenue target of $450–470 million.
10 January 2026
···
Eli Lilly stock slides 2%: Zepbound trial data, TuneLab AI tie-up and what’s next for LLY

Eli Lilly stock slides 2%: Zepbound trial data, TuneLab AI tie-up and what’s next for LLY

Eli Lilly shares fell 2% to $1,063.56 Friday, extending a two-day decline and lagging the broader market. The drop followed late-stage trial results for a Zepbound-Taltz drug combo and news of a $1.2 billion deal to buy Ventyx Biosciences. A Form 4 filing showed Lilly Endowment sold 292,148 shares on January 7. Lilly will present at the J.P. Morgan Healthcare Conference on January 13.
10 January 2026
···
Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

Schrödinger will integrate Eli Lilly’s AI drug discovery platform, TuneLab, into its LiveDesign software, giving biotech teams direct access to Lilly’s predictive models. Revvity and Benchling also announced deals to offer TuneLab through their platforms. Lilly and Revvity will jointly fund access for select users, using federated learning to protect data. BigHat Biosciences will collaborate with Lilly to improve antibody developability models.
10 January 2026
····
Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in

Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in

Eli Lilly shares fell nearly 2% to $1,063.56 Friday, logging a second straight decline after hitting a 52-week high Thursday. The drop followed news that its Zepbound-Taltz drug combo outperformed Taltz alone in a late-stage trial, and a $1.2 billion deal to buy Ventyx Biosciences. Investors are watching for pricing pressures in Europe and key support near $1,060. Lilly’s next earnings call is Feb. 4.
9 January 2026
·
Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

Eli Lilly stock slips on Zepbound-Taltz trial data as Ventyx deal, pricing debate loom

Eli Lilly shares fell 2.1% after hours to $1,085.19 following late-stage data showing its Zepbound-Taltz combo met dual goals in 31.7% of psoriatic arthritis patients, versus 0.8% for Taltz alone. The company also agreed to buy Ventyx Biosciences for $1.2 billion and disclosed a $322.4 million share sale by Lilly Endowment Inc. Investors await updates at the J.P. Morgan Healthcare Conference next week.
9 January 2026
··
Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next

Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next

Eli Lilly shares rose 4.1% premarket to $1,108.09 after the company agreed to buy Ventyx Biosciences for $1.2 billion in cash. The deal, expected to close in the first half of 2026, adds oral inflammation drugs to Lilly’s pipeline. Lilly will pay $14 per Ventyx share, a 62% premium to its recent average. Investors are watching for details on pipeline progress and spending ahead of Lilly’s next earnings call.
8 January 2026
·
Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

Eli Lilly agreed to acquire Ventyx Biosciences for $14 per share in cash, valuing the company at about $1.2 billion. Ventyx shares closed up 37% at $13.81, while Lilly rose 4%. The deal is expected to close in the first half of 2026, pending shareholder approval. Investors await proxy filings and Lilly’s next earnings call for further details.
7 January 2026
···
Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus

Eli Lilly stock jumps after $1.2B Ventyx buy as obesity-pill bets come into focus

Eli Lilly shares rose 4.1% to $1,108.09 after the company agreed to acquire Ventyx Biosciences for $1.2 billion in cash. Ventyx holders will receive $14 per share, a 62% premium to its 30-day VWAP. The deal is expected to close in the first half of 2026, pending regulatory and shareholder approval. Lilly also announced a multi-year obesity drug partnership with Nimbus Therapeutics.
7 January 2026
···
Eli Lilly stock climbs on Ventyx buyout talk as dealmaking takes center stage

Eli Lilly stock climbs on Ventyx buyout talk as dealmaking takes center stage

Eli Lilly shares rose 3.3% to $1,099.44 after reports it is in advanced talks to buy Ventyx Biosciences for over $1 billion, according to the Wall Street Journal. The news follows Lilly’s new obesity-drug partnership with Nimbus and comes as Novo Nordisk launches an oral Wegovy pill in the U.S. Investors await updates at next week’s J.P. Morgan healthcare conference and Lilly’s upcoming earnings call.
7 January 2026
·
1 … 3 4 5 6 7 … 12

Stock Market Today

  • Driven Brands Holdings (DRVN) Valuation Under Scrutiny Amid Share Price Decline and Accounting Concerns
    March 22, 2026, 10:37 AM EDT. Driven Brands Holdings (DRVN) shares closed at $10.75, reflecting a 3% gain over the past week but a 37% drop in the last month and a 38% decline over 12 months. The company, valued at $1.77 billion with $2.44 billion in annual revenue and a $234 million net loss, faces pressure amid an accounting review and delayed SEC filings. Analysts set a fair value estimate of $18.81 based on predicted cash flows and expansion strategies including growth in Take 5 locations and higher-margin services. However, risks linked to earnings quality and legal issues create uncertainty. Investors are advised to weigh potential rewards against these risks and explore broader opportunities.
Go toTop